TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.

Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.

16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting…

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

BioVaria will take place in a hybrid format on May 11 and 12, 2022 - live at the Sofitel in Munich and virtually. 14 technology transfer partners from five European countries will present more than 50 commercially attractive licensing opportunities. Application for the Startup Pitch & Partner programme is now open until March 1, 2022.

Céline Christiansen has joined the Berlin team as technology scout. She will closely work with MDC and Charité scientists, supporting them in all IP- and transfer-related aspects of their work.

The financing round was supported by a selected network of investors from medical and financial sectors. It enables the start-up to advance its fully automated ‘lab-in-a-box’ system for the molecular diagnosis of skin diseases to the market.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

On 30 November 2021, Ascenion will host the first GO-Bio Information Webinar as part of our BMBF-funded Life Science Digital Hub project. Participants…

Three projects from Ascenion’s partner institute have been awarded translational funding. Two of the teams hope to develop novel antivirals, the third is working to create a new diagnostic platform.

The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.

We have all seen the digital health trend approaching – but it has nevertheless surprised us with its speed and force. Here our summary of last year’s highlights, start-up projects and key figures, in the field of digital health and beyond.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

Ascenion welcomes two new colleagues: Rebecca Engels is coordinating Ascenion’s activities in the GO-Bio initial programme from our Munich office, and Arturo Robertazzi supports our Berlin team as technology manager.

Be part of Munich’s vibrant bioentrepreneurial ecosystem and sign up now! In 2021, the event will be delivered in a fully virtual format.

Ankara, Turkey

Cologne, Germany

Munich, Germany

Kiel, Germany